Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Neoptolemos, John P. (VerfasserIn) , Hackert, Thilo (VerfasserIn) , Büchler, Markus W. (VerfasserIn)
Dokumenttyp:	Article (Journal)
Sprache:	Englisch
Veröffentlicht:	March 11, 2017
In:	The lancet Year: 2017, Jahrgang: 389, Heft: 10073, Pages: 1011-1024
ISSN:	1474-547X
DOI:	10.1016/S0140-6736(16)32409-6
Online-Zugang:	Verlag, Volltext: http://dx.doi.org/10.1016/S0140-6736(16)32409-6 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0140673616324096
Verfasserangaben:	John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R Izbicki, Gary William Middleton, Sebastian Cummins, Paul J Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting Ma, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W Büchler, for the European Study Group for Pancreatic Cancer